Profile: Ortec Intl., Inc. is a provider of orcel bilayered cellular matrix, a living skin equivalent which is approved for use in the management of donor sites in burn patients and in hand reconstructive surgery in patients with epidermolysis bullosa. The preliminary data from a venous ulcer trial showed that at 12 weeks, 64% of orcel treated patients achieved 100% wound closure in comparison to 39.1% for the control group treated with standard of care. A differential in healing of orcel over standard of care becomes apparent after the first week and is maintained throughout the 12 week period.

The company was founded in 1991, has revenues of USD 1-5 Million, has ~30 employees and is ISO certified. OTC:OTCI (SEC Filings)